Evidence map›Paper›PMID 38948706›Full record

ArticlebioRxiv : the preprint server for biology2024

Transcriptional pathobiology and multi-omics predictors for Parkinson's disease.

Ruifeng Hu, Ruoxuan Wang, Jie Yuan, Zechuan Lin, Elizabeth Hutchins, Barry Landin, Zhixiang Liao, Ganqiang Liu, Clemens R Scherzer, Xianjun Dong

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ruifeng HuAPDA Center for Advanced Parkinson Research, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Ruoxuan WangAPDA Center for Advanced Parkinson Research, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jie YuanAPDA Center for Advanced Parkinson Research, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Zechuan LinAPDA Center for Advanced Parkinson Research, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Elizabeth HutchinsNeurogenomics Division, Translational Genomics Research Institute (TGen), Phoenix, AZ, USA.
Barry LandinTechnome, Herndon, Virginia, USA.
Zhixiang LiaoAPDA Center for Advanced Parkinson Research, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Ganqiang LiuAPDA Center for Advanced Parkinson Research, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Clemens R ScherzerAPDA Center for Advanced Parkinson Research, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Xianjun DongAPDA Center for Advanced Parkinson Research, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Funding

NINDS Biomarker RepositoryU24NS095871 · NINDS · INDIANA UNIVERSITY INDIANAPOLIS · PI TATIANA M. FOROUD · 2015 to 2026
$18.3M
Integrative Multi-Omic Discovery of Proximal Mechanisms Driving Age-Dependent NeurodegenerationRF1AG057331 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI FEANY, MEL B, FRAENKEL, ERNEST · 2017 to 2017
$4.8M
Genome-Wide Prediction of Dementia in Parkinson's DiseaseR01NS115144 · NINDS · YALE UNIVERSITY · PI SCHERZER, CLEMENS R · 2019 to 2025
$4.4M
GBA pathway markers for Lewy body dementiasU01NS100603 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHERZER, CLEMENS R · 2016 to 2020
$2.9M
Biomarkers for early intervention in Parkinson diseaseU01NS082157 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHERZER, CLEMENS R · 2012 to 2016
$2.5M
Parkinson Disease: Predicting the FutureU01NS095736 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHERZER, CLEMENS R · 2016 to 2018
$2.1M
AI2AMP-PD: Accelerating Parkinsons Diagnosis using Multi-omics and Artificial IntelligenceU01NS120637 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI DONG, XIANJUN, SCHERZER, CLEMENS R · 2020 to 2020
$537k
NIA NIH HHS RF1 AG057331NINDS NIH HHS R01 NS115144NINDS NIH HHS U01 NS082157NINDS NIH HHS U01 NS095736NINDS NIH HHS U01 NS100603NINDS NIH HHS U01 NS120637NINDS NIH HHS U24 NS095871
6 · The paper itself

Abstract

Early diagnosis and biomarker discovery to bolster the therapeutic pipeline for Parkinson's disease (PD) are urgently needed. In this study, we leverage the large-scale whole-blood total RNA-seq dataset from the Accelerating Medicine Partnership in Parkinson's Disease (AMP PD) program to identify PD-associated RNAs, including both known genes and novel circular RNAs (circRNA) and enhancer RNAs (eRNAs). There were 1,111 significant marker RNAs, including 491 genes, 599 eRNAs, and 21 circRNAs, that were first discovered in the PPMI cohort (FDR < 0.05) and confirmed in the PDBP/BioFIND cohorts (nominal

Indexed as

Biological SciencesDifferentially expressed genesMachine learningNeuroscienceNeutrophil activationParkinson’s disease

Identifiers

PMID38948706
PMCPMC11212969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.